- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00913614
Single Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluation of Eplivanserin in Children With Insomnia (PKiDs)
Single Dose, Open Label Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluation of Three Different Eplivanserin Doses in Children Aged 6-17 Years With Insomnia of Various Origins
Given the potential age-related differences in safety, tolerability, pharmacokinetics, and differences in sleep architecture in young children versus adolescent versus adult, studies to identify the appropriate drug and dosage for children of all ages are essential in addressing this health problem that impacts the child and their family. The objective of this study is to evaluate the safety, pharmacokinetics and preliminary efficacy of eplivanserin.
Primary objective: to assess the safety and tolerability after administration of single ascending oral doses of eplivanserin to children aged 6-17 years with insomnia of various origins.
To assess the pharmacokinetics of eplivanserin (and active metabolite: SR141342) after administration of single ascending oral doses of eplivanserin to children aged 6-17 years with insomnia of various origins.
Secondary objective: to assess the effect of single ascending oral doses of eplivanserin on global sleep parameters and sleep architecture measured via polysomnography recordings in children aged 6-17 years old with insomnia of various origins.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New Jersey
-
Bridgewater, New Jersey, United States, 08807
- Sanofi-Aventis Administrative Office
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children with a diagnosis of insomnia of various origins.
- Complaint of childhood insomnia as defined by repeated difficulty with sleep initiation or consolidation that occurs despite adequate age appropriate time and opportunity for sleep. The existence of sleep difficulty will be supported by statements from the child and/or the caregiver that sleep is not properly initiated or maintained.
- Written consent must be obtained from the parent/legal guardian.
- Written assent must be obtained from children of the appropriate age who are capable of giving assent as determined by parent/legal guardian.
Exclusion Criteria:
- The sleep disturbance must not be attributable to either the direct physiologic effect of a drug of abuse or misuse of a prescribed medication.
- Subject, if female of childbearing potential, which are unwilling to abstain from sexual intercourse or practice a double contraception method for the length of the study.
- Mental retardation.
- The presence of any untreated or uncompensated clinically significant renal, endocrine, hepatic, respiratory, cardiovascular, neurologic (excluding ADHD), hematologic, immunologic, cerebrovascular disease, or malignancy.
- Subjects with a history of any significant gastrointestinal disease.
- Presence of drug or alcohol abuse within one year before inclusion.
- Current history of substance abuse/dependence.
- Pregnant or breast-feeding.
- Use of any hypnotics/psychotropics, antihistamines, melatonin, herbal products, or other sleep aids including clonidine for initiation or maintenance of sleep within one week or five half lives (whichever is longer), prior to screening and unwillingness to discontinue them at the screening visit.
- Subject tested positive at screening or at baseline or at Day 1, on urine drug screen for drugs known to alter sleep (amphetamine/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates and alcohol).
- Inability to swallow a pill in similar size as the tablets to be administered for this study.
- Current or recent (<60 days) participation in another clinical trial receiving an investigational drug.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Age Group 6-11 year old - Dose level 1
|
Oral administration
|
Experimental: Age Group 6-11 year old - Dose Level 2
|
Oral administration
|
Experimental: Age Group 6-11 year old - Dose Level 3
|
Oral administration
|
Experimental: Age Group 12-17 year old - Dose level 1
|
Oral administration
|
Experimental: Age Group 12-17 year old - Dose level 2
|
Oral administration
|
Experimental: Age Group 12-17 year old - Dose level 3
|
Oral administration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety in terms of adverse events, laboratory tests, vital signs, ECGs
Time Frame: Up to 12 days following single dose administration
|
Up to 12 days following single dose administration
|
Pharmacokinetics parameters
Time Frame: on Day 1, Day 2, Day 5, Day 7 and Day 10
|
on Day 1, Day 2, Day 5, Day 7 and Day 10
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Global sleep parameters
Time Frame: Immediately following single dose administration
|
Immediately following single dose administration
|
Sleep architecture
Time Frame: Immediately following single dose administration
|
Immediately following single dose administration
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Sleep Initiation and Maintenance Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Serotonin Agents
- Serotonin Antagonists
- SR 46349B
Other Study ID Numbers
- PKD10491
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep Initiation and Maintenance Disorders
-
Merck Sharp & Dohme LLCCompletedDyssomnias | Sleep Disorders | Mental Disorder | Sleep Initiation and Maintenance Disorder; Elderly | Sleep Disorder, Intrinsic
-
Eisai Co., Ltd.RecruitingSleep Initiation and Maintenance DisordersKorea, Republic of
-
Shanghai Institute of Acupuncture, Moxibustion...Shanghai University of Traditional Chinese MedicineNot yet recruitingSleep Initiation and Maintenance DisordersChina
-
Saint Vincent's Hospital, KoreaCompletedSleep Initiation and Maintenance DisordersKorea, Republic of
-
Chang Gung Memorial HospitalUnknownSleep Initiation and Maintenance DisordersTaiwan
-
Seattle Children's HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development...UnknownSleep Initiation and Maintenance DisordersUnited States
-
Marmara UniversityCompletedSleep Initiation and Maintenance Disorders
-
GlaxoSmithKlineCompletedSleep Initiation and Maintenance DisordersUnited States
-
Boehringer IngelheimCompletedSleep Initiation and Maintenance Disorders
-
Astellas Pharma IncCompletedSleep Initiation and Maintenance DisordersJapan
Clinical Trials on Eplivanserin (SR46349)
-
SanofiCompletedInsomnia | Sleep Initiation and Maintenance DisordersUnited States, France, Germany, Netherlands, Spain, Czech Republic, Mexico, United Kingdom, Argentina, Austria, Finland, Chile, Canada, Australia
-
SanofiCompletedPrimary InsomniaUnited States, France, Canada, Poland, Germany, Hungary, Austria
-
SanofiCompletedChronic Pain | Sleep | FibromyalgiaUnited States, Canada
-
SanofiCompletedInsomnia | Sleep Initiation and Maintenance DisordersUnited States, France, Canada, Australia, Germany, Netherlands, Spain, Czech Republic, Mexico, United Kingdom, Argentina, Chile
-
SanofiCompletedInsomnia | Sleep Initiation and Maintenance DisordersCanada, United States, Australia
-
SanofiCompletedSleep Initiation and Maintenance DisordersFrance, Netherlands, Portugal, Spain, Estonia, Finland, Norway, Chile
-
Assiut UniversityUnknown